stockrowCogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) EV/Sales
As of 6 November 2026, Cogent Biosciences, Inc. (COGT) trades at a EV/Sales of 209×. Over the past ten years it has ranged from −6.7× (March 2021) to 292× (August 2026); the current reading is higher than 94% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | −4.9× | — |
| FY2019 | −0.5× | — |
| FY2018 | 3.2× | (63.11%) |
| FY2017 | 8.6× | 0.00% |
| FY2016 | 8.6× | 0.00% |
| FY2015 | 8.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2020 | 4.5× | — |
| Jun 2020 | −0.1× | — |
| Mar 2020 | −0.5× | — |
| Dec 2019 | −0.5× | — |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ERAS Erasca, Inc. compare | n/m |
| MANE Veradermics Incorporated compare | n/m |
| KOD Kodiak Sciences Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 5.4× |
| TVTX Travere Therapeutics, Inc. compare | 7.4× |
| SRRK Scholar Rock Holding Corporation compare | 123× |
| CRSP CRISPR Therapeutics AG compare | 125× |
| COGT Cogent Biosciences, Inc. | 209× |
| DNTH Dianthus Therapeutics, Inc. compare | 1,515× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement